Projects per year
Personal profile
Research Area Keywords
- Neurosciences
- Clinical Translation & Trials
Fingerprint
Dive into the research topics where Sheetal Shroff is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Phase 1/2, Open-Label, Multicenter, Dose Finding and Dose Expansion Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants with BAG3 Mutation Associated Dilated Cardiomyopathy
Kassi, M. (PI) & Shroff, S. (Key Personnel)
11/25/25 → …
Project: Clinical Trial
-
Phase 2 study evaluating rapcabtagene autoleucel in participants with severe active GPA or MPA
Kazzaz, S. (PI), Ganguly, S. (Key Personnel), Guevara, M. (Key Personnel), Monga, K. (Key Personnel), Pingali, S. R. (Key Personnel) & Shroff, S. (Key Personnel)
10/29/25 → …
Project: Clinical Trial
-
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Antisense Oligonucleotide AMX0114 Administered to Adult Participants with Amyotrophic Lateral Sclerosis
Shroff, S. (PI), Greene, E. P. (Key Personnel) & Liao, B. (Key Personnel)
8/5/25 → …
Project: Clinical Trial
-
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects with Non-Oncology Plasma Cell-Related Diseases
Liao, B. (PI), Ganguly, S. (Key Personnel), Greene, E. P. (Key Personnel) & Shroff, S. (Key Personnel)
5/12/25 → …
Project: Clinical Trial
-
An open-label, multi-center, phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis.
Greene, E. P. (PI), Liao, B. (Key Personnel) & Shroff, S. (Key Personnel)
5/8/25 → …
Project: Clinical Trial
-
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial
Authors/Writing Committee for the HEALEY ALS Platform Trial, Apr 1 2025, In: JAMA: The Journal of the American Medical Association. 333, 13, p. 1138-1149 12 p.Research output: Contribution to journal › Article › peer-review
Open Access9 Scopus citations -
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis A Randomized Clinical Trial
the HEALEY ALS Platform Trial Study Group, Feb 3 2025, In: JAMA Network Open. e2459058.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial
Authors/Writing Committee for the HEALEY ALS Platform Trial, Apr 1 2025, In: JAMA: The Journal of the American Medical Association. 333, 13, p. 1128-1137 10 p.Research output: Contribution to journal › Article › peer-review
Open Access10 Scopus citations -
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study
on behalf of the MG0004 study investigators, Apr 2025, In: Journal of Neurology. 272, 4, 275.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial
HEALEY ALS Platform Trial, Apr 14 2025, In: JAMA Neurology. 82, 4, p. 333-343 11 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations